Douglas J Watson
Affiliation: Merck Research Laboratories
- Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritisDouglas J Watson
Department of Epidemiology, Merck Research Laboratories, 10 Sentry Pkwy BL1 7, Blue Bell, PA 19422, USA
Arch Intern Med 162:1105-10. 2002..Naproxen strongly inhibits platelet aggregation...
- Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of AgingElizabeth A Platz
Department of Epidemiology, Room E6138, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA
Cancer Epidemiol Biomarkers Prev 14:390-6. 2005..We evaluated the association of aspirin and nonaspirin NSAIDs with subsequent prostate cancer in a prospective study. We also assessed whether use of these drugs influences serum prostate-specific antigen (PSA) concentration...
- Validation of a questionnaire to assess niacin-induced cutaneous flushingJosephine M Norquist
Merck Research Laboratories, Department of Epidemiology, North Wales, PA 19454 2505, USA
Curr Med Res Opin 23:1549-60. 2007..To further characterize flushing, a patient-reported Flushing Symptom Questionnaire (FSQ) was developed and validated...
- All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research DatabaseDouglas J Watson
Department of Epidemiology, Biostatistics and Research Decision Sciences, Merck Research Laboratories West Point, Pennsylvania 19422, USA
J Rheumatol 30:1196-202. 2003..Much smaller elevations in risk have been found in the few community-based studies that have addressed this question...
- Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaJohn F Paolini
Merck Research Laboratories, Rahway, NJ, USA
Am J Cardiol 101:625-30. 2008..LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients...
- Dosage, titration, and gaps in treatment with extended release niacin in clinical practiceSachin J Kamal-Bahl
Merck and Co Inc, West Point, PA, USA
Curr Med Res Opin 24:1817-21. 2008..To examine the dosage, titration patterns, and gaps in treatment of newly-initiated ER niacin in clinical practice...
- Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interviewSachin Kamal-Bahl
Merck and Co, Inc, West Point, Pennsylvania, USA
Clin Ther 31:130-40. 2009..Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing...
- The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysisDena R Ramey
Epidemiology, Merck Research Laboratories, West Point, PA 19486, USA
Curr Med Res Opin 21:715-22. 2005....
- The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisDouglas J Watson
Merck Research Laboratories, West Point, PA, USA
Curr Med Res Opin 20:1539-48. 2004..Rofecoxib, a COX-2 specific inhibitor, was developed to provide similar efficacy and less GI toxicity than NSAIDs...
- Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care settingKathleen A Foley
Department of Epidemiology, Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
Manag Care Interface 17:21-6. 2004..Given the high prevalence of arthritic conditions, these results suggest that the selection of a COX-2 inhibitor may substantially affect health care costs...
- Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertensionAlan Morrison
SCRIBCO, P O Box 1525, Blue Bell, PA 19422, USA
Curr Med Res Opin 23:2395-404. 2007..To investigate the effects of continued use of non-selective NSAIDs (nsNSAIDs) on blood pressure and hypertension...
- Observational studies and the withdrawal of rofecoxibDouglas J Watson
Department of Epidemiology, Merck Research Laboratories, West Point, PA, USA
Pharmacoepidemiol Drug Saf 15:199-201; author reply 203-5. 2006
- Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature reviewPaul Emery
Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds, United Kingdom
Clin Ther 24:1225-91. 2002..There is a need for clinical trials directly addressing dose-effect relationships of NSAIDs, as well as reviews of more current literature and reports in languages other than English...
- Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritisJames M Pellissier
Ann Intern Med 140:761; author reply 761-2. 2004
- Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concernDouglas J Watson
Drug Saf 30:89-90; author reply 90-1. 2007
- Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort studyElham Rahme
Department of Medicine McGill University, and Research Institute, McGill University Health Center, Montreal, Canada
Pharmacoepidemiol Drug Saf 16:493-503. 2007..To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population...
- The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal eventsRichard H Hunt
Division of Gastroenterology, McMaster University Medical Center, Hamilton, Ontario, Canada
Am J Gastroenterol 98:1725-33. 2003..Treatment with etoricoxib reduced the incidence of investigator-reported and confirmed adverse upper GI events by approximately 50% compared with treatment with nonselective NSAIDs...
- An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritisThomas J Schnitzer
Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
Clin Ther 25:3162-72. 2003..However, these conclusions are limited by lack of clinical information (other than an OA or RA diagnosis), inability to ascertain actual use, and potential for selection bias...
- Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medicationsPriscilla Velentgas
Ingenix i3 Drug Safety, Auburndale, MA 02466, USA
Pharmacoepidemiol Drug Saf 15:641-52. 2006..The purpose of this study was to estimate rates of acute coronary syndrome (ACS), and sudden cardiac death in relation to use of rofecoxib, celecoxib, naproxen, diclofenac, and ibuprofen...
- Guidelines for good pharmacoepidemiology practices (GPP)Elizabeth B Andrews
Pharmacoepidemiol Drug Saf 17:200-8. 2008
- Liver function testing in patients on HMG-CoA reductase inhibitorsSusan E Andrade
Department of Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA
Pharmacoepidemiol Drug Saf 12:307-13. 2003..We sought to determine the frequency and patterns of LFT screening in patients receiving HMG-CoA reductase inhibitors...
- Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort studyAndrew L Avins
Kaiser Permanente Division of Research, Oakland, CA 94612, USA
Drug Saf 31:325-34. 2008..Little is known about the potential adverse hepatic effects of HMG-CoA reductase inhibitors ('statins') in patients with existing liver disease; therefore, we examined the risk of liver toxicity with lovastatin exposure in these patients...